Les maladies inflammatoires chroniques de l " intestin, John Libbey Eurotext, vol.178, 1998. ,
Incidence of inflammatory bowel disease in northern France Gut, 1988. ,
Maladie de Crohn et Rectocolite Hemorragique. Médi-text éd. Paris, 2005. ,
Maladies inflammatoires chroniques de l " intestin. Doin. Rueil- Malmaison, 2009. ,
Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)., Gut, vol.39, issue.5, pp.690-697, 1996. ,
DOI : 10.1136/gut.39.5.690
Epidemiology and Natural History of Inflammatory Bowel Diseases, Gastroenterology, vol.140, issue.6, pp.1785-94, 2011. ,
DOI : 10.1053/j.gastro.2011.01.055
URL : https://hal.archives-ouvertes.fr/hal-00631553
Environmental Risk Factors for Inflammatory Bowel Diseases: A Review, Digestive Diseases and Sciences, vol.141, issue.Suppl 2, pp.367-74 ,
DOI : 10.1007/s10620-014-3350-9
Prior appendectomy and the phenotype and course of Crohn " s disease, World J Gastroenterol WJG, 2006. ,
Appendectomy and Protection against Ulcerative Colitis, New England Journal of Medicine, vol.344, issue.11, pp.808-822, 2001. ,
DOI : 10.1056/NEJM200103153441104
Toxicité des AINS pour les patients MICI : mythes ou réalité?, 2014. ,
Inflammatory bowel disease: Pathogenesis, World Journal of Gastroenterology, vol.20, issue.1, pp.91-100, 2014. ,
DOI : 10.3748/wjg.v20.i1.91
Les manifestations h??patobiliaires au cours des MICI, 2009. ,
DOI : 10.1007/978-2-287-99247-6_1
Extraintestinal manifestations and complications in inflammatory bowel diseases, World J Gastroenterol WJG Aug, vol.1412, issue.30, pp.4819-4850, 2006. ,
Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management, Annals of Medicine, vol.9, issue.7, 2010. ,
DOI : 10.2165/00002018-200023050-00006
The risk of colorectal cancer in ulcerative colitis: a meta-analysis, Gut, vol.48, issue.4, pp.526-561, 2001. ,
DOI : 10.1136/gut.48.4.526
ANCA and ASCA antibodies in the differential diagnosis between ulcerative rectocolitis and Crohn " s disease], Recenti Prog Med, vol.93, issue.5, pp.308-321, 2002. ,
Optimal use of biologics in the management of Crohn " s disease. Ther Adv Gastroenterol, pp.179-89, 2010. ,
P087 - SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy, Journal of Crohn's and Colitis, vol.3, issue.1, pp.45-51, 2009. ,
DOI : 10.1016/S1873-9946(09)60114-8
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator???activated receptor-??, The Journal of Experimental Medicine, vol.7, issue.8, pp.1205-1220, 2005. ,
DOI : 10.1136/gut.51.5.659
URL : https://hal.archives-ouvertes.fr/hal-00187736
Étude Thérapeutique des Affections Inflammatoires du Tube Digestif [Internet], Disponible sur, 2014. ,
Review article: thiopurines in inflammatory bowel disease, Alimentary Pharmacology and Therapeutics, vol.12, issue.1, pp.715-744, 2006. ,
DOI : 10.1016/0168-8278(91)90916-Y
Disponible sur : http://www.sante.gouv.fr/IMG/pdf/tableau_dispositif_perenne_3_octobre.pdf 44, tableau dispositif perenne 3 octobre -tableau_dispositif_perenne_3_octobre.pdf [Internet]. [consulté le 5 oct 2014] Takeda reçoit une AMM européenne pour Entyvio® MyPharma Editions | L " Info Industrie & Politique de Santé [Internet]. [consulté le 5 oct 2014]. Disponible sur ,
Europe autorise l " anticorps vedolizumab, p.3600655 ,
Ciprofloxacine et métronidazole en association dans la maladie de Crohn évolutive, Pulsus Group Inc ,
Concerns of patients with inflammatory bowel disease: a review of emerging themes, Dig Dis Sci, 2000. ,
Psychological factors and inflammatory bowel disease: A review of a decade of literature, Psychology, Health & Medicine, vol.13, issue.2, pp.121-156, 2001. ,
DOI : 10.1111/j.1600-0447.1983.tb09716.x
Compliance, therapeutic observance and therapeutic adherence: what do we speak about?]. Rev Mal Respir, Feb, vol.22, issue.1, pp.31-35, 2005. ,
URL : https://hal.archives-ouvertes.fr/hal-00374378
Education, psychology and ???compliance???, Diabetes/Metabolism Research and Reviews, vol.27, issue.S1, pp.101-106, 2008. ,
DOI : 10.1002/dmrr.851
Treatment adherence and chronic inflammatory bowel diseases]. Presse Médicale Paris Fr 1983, pp.1236-1279, 2007. ,
Factors Associated With Non-Adherence to Oral Medication for Inflammatory Bowel Disease: A Systematic Review, The American Journal of Gastroenterology, vol.94, issue.3, pp.525-564, 2010. ,
DOI : 10.1038/ajg.2009.685
Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire, European Journal of Gastroenterology & Hepatology, vol.8, issue.12, pp.1179-83, 1996. ,
DOI : 10.1097/00042737-199612000-00009
Medication Non-adherence is Associated with Increased Medical Health Care Costs, Digestive Diseases and Sciences, vol.31, issue.11, pp.1020-1024, 2008. ,
DOI : 10.1007/s10620-007-9968-0
Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis, The American Journal of Medicine, vol.114, issue.1, pp.39-43, 2003. ,
DOI : 10.1016/S0002-9343(02)01383-9
Disease-Specific Knowledge, Coping, and Adherence in Patients with Inflammatory Bowel Disease, Digestive Diseases and Sciences, vol.12, issue.10, pp.2972-2979, 2011. ,
DOI : 10.1007/s10620-011-1714-y
Relationships between beliefs about medications and nonadherence to prescribed chronic medications. Ann Pharmacother, 2006. ,
DOI : 10.1345/aph.1h153
Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, vol.18, issue.Suppl. A, pp.1097-108, 2013. ,
DOI : 10.1111/apt.12476
Risk factors for non-adherence to medication in inflammatory bowel disease patients, Aliment Pharmacol Ther, vol.27, issue.2, pp.166-72, 2008. ,
The Information Needs and Preferences of Persons with Longstanding Inflammatory Bowel Disease, Canadian Journal of Gastroenterology, vol.26, issue.8, pp.525-556, 2012. ,
DOI : 10.1155/2012/735386
What do patients need to know? Living with inflammatory bowel disease, Journal of Clinical Nursing, vol.12, issue.11-12, pp.11-121718 ,
DOI : 10.1111/jocn.12321
Use of complementary and alternative medicine in patients with inflammatory bowel disease: results of a cross-sectional study in Norway, Scand J Gastroenterol, 2012. ,
WHO_EDM_TRM_2000.1_fre.pdf?ua=1 66. (Microsoft Word -Rapport M\351d Compl \340 l " AP-HP 19 062012.doc) - Rapport_Med_Compl_AP-HP-05-20122, Disponible surHP-05-20122.pdf 67. Complementary, Alternative, or Integrative Health: What " s In a Name? [Internet]. NCCAM, 2000. ,
Use of complementary and alternative medicine by patients with inflammatory bowel disease, Inflammatory Bowel Diseases, vol.17, issue.2, pp.655-62, 2011. ,
DOI : 10.1002/ibd.21360
Complementary and Alternative Medicine Use by Patients with Inflammatory Bowel Disease: An Internet Survey, Canadian Journal of Gastroenterology, vol.13, issue.4, pp.327-359, 1999. ,
DOI : 10.1155/1999/586765
An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease (IBD), Gastroenterology, vol.114, issue.5, pp.1298-303, 1999. ,
DOI : 10.1016/S0016-5085(98)84340-0
The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products, Gut, vol.61, issue.4, 2012. ,
DOI : 10.1136/gutjnl-2011-300219
Use of Complementary Therapies by Patients with IBD May Indicate Psychosocial Distress, Inflammatory Bowel Diseases, vol.8, issue.3, 2002. ,
DOI : 10.1097/00054725-200205000-00003
Impact of complementary and alternative medicine on the quality of life in inflammatory bowel disease, European Journal of Gastroenterology & Hepatology, vol.26, issue.3, pp.288-94, 2014. ,
DOI : 10.1097/MEG.0000000000000040
enquête et ses méthodes : l " entretien, 2001. ,
Méthodologie du recueil d " informations: Fondements des méthodes d " observation, de questionnaires, d " interviews et d " études de documents, 2009. ,
Facteurs environnementaux dans la maladie de Crohn. Acta Endosc, pp.679-88, 2006. ,
DOI : 10.1007/bf03018510
Progrès en hépatogastroentérologie. Paris: Doin éditeur, 1988. ,
Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis, J Manag Care Pharm JMCP, vol.18, issue.9, pp.701-713, 2012. ,
Perceptions of medication safety among patients with inflammatory bowel disease, Scandinavian Journal of Gastroenterology, vol.90, issue.9, 2010. ,
DOI : 10.1016/j.cgh.2008.08.029
Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease, Expert Opinion on Drug Safety, vol.19, issue.6, 2011. ,
DOI : 10.1016/j.crohns.2009.10.002